Trovagene

Get Full Access

Description

  • Trovagene is a biotechnology company developing oncology therapeutics for improved cancer care by leveraging its proprietary Precision Cancer Monitoring® (PCM) technology in tumor genomics.  Trovagene has broad intellectual property and proprietary technology to measure circulating tumor DNA (ctDNA) in urine and blood to identify and quantify clinically actionable markers for predicting response to cancer therapies.  Trovagene offers its PCM technology at its CLIA/CAP accredited laboratory and plans to continue to vertically integrate its PCM technology with precision cancer therapeutics. Trovagene's lead therapeutic asset is PCM-075, an oral, investigational drug and a highly-selective polo-like kinase 1 (PLK1) inhibitor for the treatment of acute myeloid leukemia (AML). Among the four members of the PLK family, PLK1 is recognized to be the fundamental component for cell division to take place correctly. Most importantly, PLK1 is only expressed in dividing cells, whereas other PLK members are expressed in differentiated post-mitotic cells, like neurons, indicating a potentially better safety profile for a PLK1-selective inhibitor, such as PCM-075. The greatest clinical activity for PLK inhibitors has been observed in AML, which may likely be due to the highly proliferative nature of AML tumors. Trovagene's interest in PLK inhibitors stems from this observed PLK clinical activity and the opportunity for a more selective therapeutic approach. The properties of PCM-075 are PLK1 selectivity, the only orally-available PLK inhibitor in clinical development, a short half-life of ~24 hours with reversible hematologic toxicities, and an acceptable safety profile in humans with no adverse respiratory or cardiovascular effects. Trovagene plans to conduct a phase II trial for determining dose, patient response and correlative biomarker analysis for patients with AML. For more information, please visit our website www.trovagene.com.
  • location

    Headquarters:11055 Flintkote Avenue , San Diego, California, United States

    More
  • Trovagene phone

    Phone Number: +1 858-952-7570

  • Trovagene website

    Website: http://www.trovagene.com/

  • Trovagene employees

    Employees:31

  • Trovagene revenue

    Revenue:$10 - 50M

  • Trovagene legal name

    Legal Name:Trovagene

  • Trovagene's Social Media

    Trovagene linkedin Trovagene facebook Trovagene twitter
  • done Is this data correct?
  • |  NAICS Code: 541713  |

    Show More
Person level website identification

CEO for Trovagene

Tom Adams

Chairman And Chief Executive Officer

Person level website visitor identification

Sell more in less time!

Buyer intent data, anonymous visitor identification, first party data integration backed by a massive contact database that will supercharge your sales team. Schedule a demo to learn more!

View Employees

Vicki Kelemen

Chief Operating Officer

Brigitte Lindsay

Vice President Finance And Principal Financial Officer

Elizabeth Anderson

Vice President, Finance

Chuck Monahan

Senior Vice President Regulatory Affairs

Renee Tannenbaum

Board Director

Frequently Asked Questions regarding Trovagene

  • Where are Trovagene's Headquarters?

    Trovagene's Headquarters are in 11055 Flintkote Avenue ,San Diego,California,United States

  • What is Trovagene's phone number?

    Trovagene's phone number is +1 858-952-7570

  • What is Trovagene's official website?

    Trovagene's official website is http://www.trovagene.com/

  • What is Trovagene's Revenue?

    Trovagene's revenue is $10 - 50M

  • What is Trovagene's NAICS code?

    Trovagene's NAICS code is 541713

  • How many employees are working in Trovagene

    Trovagene has 31 employees

  • What is Trovagene's Industry?

    Trovagene is in the industry of Biotechnology

  • Who is Trovagene's CEO?

    Trovagene's CEO is Tom Adams

Company Directory